Loss of smell may affect over 20% of the population, specifically among older age groups and can result in significant health impacts. Smell loss can substantially affect an individual's overall well-being and quality of life. The purpose of this study is to evaluate the impacts of smell loss on neurologic disease (such as Alzheimer's and dementia) and on the risk of death over a 10-year period. We hypothesize that decreased sense of smell is associated with development of neurodegenerative disease and mortality. Participants in this study will fill out an electronic questionnaire (about 30 minutes long) at study entry, and a shortened electronic questionnaire (about 15 minutes long) every year after that for 10 years. No in-person visits are needed.
ATHN 9 is a natural history study to assess the safety of various Von Willebrand Factor (VWF) regimens for different indications (on-demand, surgery and prophylaxis) in adult and pediatric participants with clinically severe congenital VWD.